Skip to main content
    F

    Fortress Biotech Inc (FBIO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.71
    -0.17 (-9.04%)

    Market Cap: $62.70M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Fortress Biotech Inc (FBIO) Earnings: Report Dates and Results

    Updated Nov 13, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Fortress Biotech (FBIO) is expected to report earnings on Mar 29, 2027. In the quarter ended Sep 30, 2026, Fortress Biotech reported EPS of -$0.23, above the -$0.27 estimate. It beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    49%(19/39)
    Avg Surprise
    -31.33%
    Streak
    2 Q

    Upcoming Estimates

    Reports Mar 29, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.26
    RangeN/A
    3 analysts
    Revenue Consensus
    $22.91M
    Range$22.01M - $23.59M
    3 analysts

    Next Report

    FBIO has an expected report date of Mar 29, 2027.

    FBIO Earnings Call

    The latest FBIO earnings call transcript on file is labeled 2026Q2.

    Read the 2026Q2 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, FBIO beat 19, missed 19 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $19.16M, up 8.7% from $17.63M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.23-$0.27-$0.27 - -$0.27+14.81%Beat-309.1%10 up, 1 downNov 13, 2026$19.16M
    Jun 30, 2026-$0.08-$0.20-$0.20 - -$0.20+60.00%BeatN/A10 up, 1 downAug 13, 2026$18.72M
    Mar 31, 2026$2.82-$0.22-$0.22 - -$0.22N/AN/AN/A10 up, 0 downMay 14, 2026$16.04M
    Dec 31, 2025-$0.21$0.11-$0.20 - $0.42-290.91%MissN/A21 up, 0 downMar 31, 2026$16.08M
    Sep 30, 2025$0.11-$0.62-$0.84 - -$0.41+117.74%BeatN/A20 up, 1 downNov 14, 2025$17.63M
    Jun 30, 2025-$0.51-$0.31-$0.31 - -$0.31-64.52%MissN/A11 up, 0 downAug 14, 2025$16.41M
    Mar 31, 2025-$0.48-$0.44-$0.44 - -$0.44-9.09%MissN/A10 up, 0 downMay 21, 2025$13.14M
    Dec 31, 2024-$0.30-$0.75-$0.75 - -$0.75+60.09%BeatN/A10 up, 1 downMar 27, 2025$15.16M
    Sep 30, 2024-$0.76-$0.27-$0.92 - -$0.27-181.48%MissN/A20 up, 0 downNov 14, 2024$14.63M
    Jun 30, 2024-$0.73-$1.22-$1.75 - -$0.88+40.16%BeatN/A30 up, 0 downAug 13, 2024$14.86M
    Mar 31, 2024-$1.03-$1.73-$2.60 - -$1.13+40.46%BeatN/A30 up, 0 downMay 15, 2024$13.03M
    Dec 31, 2023-$1.28-$1.97-$2.61 - -$1.49+35.03%BeatN/A31 up, 0 downMar 28, 2024$19.95M
    Sep 30, 2023-$0.94-$1.50N/A+37.33%BeatN/A50 up, 0 downNov 14, 2023$34.75M
    Jun 30, 2023-$1.05-$0.90N/A-16.67%MissN/A40 up, 0 downAug 14, 2023$17.39M
    Mar 31, 2023-$0.90$0.45N/A-300.00%MissN/A40 up, 0 downMay 15, 2023$12.43M
    Dec 31, 2022-$0.30-$0.22-$0.29 - -$0.15-36.36%MissN/A40 up, 0 downMar 30, 2023$16.40M
    Sep 30, 2022-$1.20-$1.05N/A-14.29%Miss-114.8%60 up, 0 downNov 14, 2022$16.53M
    Jun 30, 2022-$1.50-$1.12-$4.65 - -$0.45-33.93%MissN/A70 up, 0 downAug 11, 2022$18.89M
    Mar 31, 2022-$1.05$0.15N/A-800.00%MissN/A31 up, 0 downMay 12, 2022$23.93M
    Dec 31, 2021-$0.38$0.18-$0.14 - $0.47-311.11%MissN/A50 up, 0 downMar 28, 2022$18.28M
    Sep 30, 2021$8.10-$2.85N/A+384.21%BeatN/A6N/ANov 15, 2021$21.09M
    Jun 30, 2021-$2.55-$1.80-$3.00 - -$0.30-41.67%MissN/A6N/AAug 16, 2021$17.84M
    Mar 31, 2021-$1.35-$0.70N/A-92.86%MissN/A4N/AMay 16, 2021$11.59M
    Dec 31, 2020-$0.05-$0.14-$0.18 - -$0.09+64.29%BeatN/A6N/AMar 31, 2021$13.75M
    Sep 30, 2020-$3.02-$2.10-$7.95 - -$0.75-43.81%MissN/A6N/ANov 9, 2020$9.47M
    Jun 30, 2020-$2.84-$2.50N/A-13.60%MissN/A5N/AAug 10, 2020$9.46M
    Mar 31, 2020-$2.91-$3.60-$4.05 - -$3.15+19.17%Beat-1070.0%4N/AMay 11, 2020$12.92M
    Dec 31, 2019-$0.27-$0.31-$0.43 - -$0.26+12.90%BeatN/A5N/AMar 16, 2020$11.13M
    Sep 30, 2019-$3.30-$5.10-$5.10 - -$3.90+35.29%BeatN/A2N/ANov 12, 2019$9.77M
    Jun 30, 2019-$3.60-$6.00-$7.80 - -$6.00+40.00%BeatN/A2N/AAug 9, 2019$9.25M
    Mar 31, 2019$0.30-$8.70-$8.70 - -$8.70+103.45%BeatN/A1N/AMay 10, 2019$6.48M
    Dec 31, 2018-$0.58-$0.58-$0.58 - -$0.580.00%In lineN/A1N/AMar 18, 2019$8.99M
    Sep 30, 2018-$5.55-$8.55N/A+35.09%BeatN/A1N/ANov 9, 2018$5.17M
    Jun 30, 2018-$7.50-$8.80-$11.09 - -$6.45+14.77%BeatN/A3N/AAug 9, 2018$6.82M
    Mar 31, 2018-$7.35-$6.00-$7.20 - -$5.10-22.50%MissN/A3N/AMay 10, 2018$5.90M
    Dec 31, 2017-$0.22-$0.63-$0.68 - -$0.57+65.08%BeatN/A3N/AMar 16, 2018$45.32M
    Sep 30, 2017-$10.05-$6.37-$6.90 - -$5.85-57.77%MissN/A2N/ANov 9, 2017N/A
    Jun 30, 2017-$6.45-$4.42-$4.80 - -$4.05-45.93%MissN/A2N/AAug 9, 2017$50.70M
    Mar 31, 2017-$4.50-$5.40N/A+16.67%BeatN/AN/AN/AMay 10, 2017$44.68M
    Dec 31, 2016-$0.44-$0.31N/A-41.94%MissN/AN/AN/AMar 16, 2017$42.11M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.09, after -$2.82 the year before. It was -$10.20 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.09N/A
    Dec 31, 2024-$2.82N/A
    Dec 31, 2023-$4.17N/A
    Dec 31, 2022-$4.05-206.0%
    Dec 31, 2021$3.82N/A
    Dec 31, 2020-$8.82N/A
    Dec 31, 2019-$6.87N/A
    Dec 31, 2018-$20.98N/A
    Dec 31, 2017-$21.22N/A
    Dec 31, 2016-$10.20N/A

    Earnings Calls

    The 2 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 5,200 words across 9 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q2Jun 30, 20265,1619
    2025Q3Sep 30, 20254,8969

    2026Q2 Earnings Call

    Opening remarks

    Jaclyn Jaffe Senior Director of Corporate Operations Good afternoon, and thank you for participating in today's conference call. Joining me from Journey Medical's leadership team are Claude Maraoui, Co-Founder, President and Chief Executive Officer; Joseph Benesch, Chief Financial Officer; and Ramsey Alloush, Chief Operating Officer and General Counsel, who will participate in the Q&A portion of the call. During this call, management will be making forward-looking statements, including statements that address among other things, Journey Medical's expectations for future performance, operational results, financial condition and the receipt of regulatory approvals. Forward-looking statements involve risks and other factors that may cause actual results to differ materially from those statements. For information about these risks, please refer to the risk factors described in Journey Medical's most recently filed periodic reports on Form 10-K and Form 10-Q. The Form 8-K filed with the SEC today and the company's press release that accompanies this call, particularly the cautionary statements in it. Today's conference call includes non-GAAP financial measures that Journey Medical believes can be useful in evaluating its performance. You should not consider this additional information in isolation or as a substitute for results prepared in accordance with GAAP. For a reconciliation of this non-GAAP financial measure to net loss, its most directly comparable GAAP financial measure, please see the reconciliation table located in the company's earnings press release. The content of this call contains time-sensitive information that is accurate only as of today, Wednesday, August 12, 2026. Except as required by law, Journey Medical disclaims any obligation to publicly update or revise any information to reflect events or circumstances that occur after this call. It is now my pleasure to turn the call over to Claude Maraoui, Co-Founder, President and Chief Executive Officer of Journey Medical.

    Claude Maraoui Co-Founder, President and Chief Executive Officer Thank you, Jaclyn, and good afternoon to everyone on the call today. We continue to make solid progress in our business in the second quarter as we delivered strong revenue growth and improved profitability during the period. Emrosi revenues were $8.1 million in Q2, up significantly year-over-year and sequentially from the first quarter on higher prescription volume, improving payer reimbursement and a significant step-up in the number of dermatology writers prescribing the brand. These metrics not only trended positively, but also showed acceleration, and we expect this progress to continue in the coming quarters. Our total net product revenues for the second quarter rose by 23% year-over-year, while operating expenses increased by less than 1% compared to Q2 of last year. We remain focused on delivering strong top line growth and leveraging our proven dermatology commercial infrastructure. We are executing on these initiatives and as a result, we generated positive EBITDA in the second quarter.

    Frequently Asked Questions About FBIO

    When is Fortress Biotech's next earnings date?

    Fortress Biotech's next earnings report is expected for Mar 29, 2027.

    Did FBIO beat earnings estimates last quarter?

    Yes. Fortress Biotech reported EPS of -$0.23 for the quarter ended Sep 30, 2026, above the -$0.27 estimate, a 14.81% surprise.

    What EPS do analysts expect from FBIO next quarter?

    The consensus EPS estimate for Fortress Biotech for the quarter ending Dec 31, 2026 is -$0.26 from 3 analysts.

    How often does FBIO beat earnings estimates?

    Fortress Biotech beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate, with an average surprise of -36.67%.